A non-banking financial company that provides commercial and individual loans while managing a portfolio of strategic investments, primarily within the real estate sector.
The company lacks a durable competitive advantage, as evidenced by a massive 45.9% revenue CAGR decline and negative net margins. Returns on equity are negligible, and the business appears to function primarily as a financing vehicle for related-party real estate projects rather than a competitive lender.
Capital is primarily deployed into related-party loans and advances to group real estate concerns, many of which are facing significant regulatory and operational delays. This has resulted in the cessation of interest accruals and a lack of liquidity to meet basic statutory obligations.
The company's collapse was precipitated by the total impairment of its related-party loan book, as the underlying real estate projects failed to materialize. With interest accruals already halted and statutory TDS liabilities mounting, the lack of a functional internal audit and regulatory non-compliance led to an RBI license revocation. The business effectively liquidated as a shell, with remaining assets consumed by legal disputes and unpaid government dues, leaving equity holders with nothing but a lesson in the dangers of self-dealing.
RichFakir rates Vardhan Capital & Finance Ltd's business quality as poor — 12/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Vardhan Capital & Finance Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Vardhan Capital & Finance Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Vardhan Capital & Finance Ltd's fair value is about ₹0 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →